Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)

A majority-owned and controlled subsidiary of Fortress entered into an agreement with Cedars-Sinai to license FB-607, which is currently being evaluated in an ongoing Phase 2 study for IBS-DMIAMI, Nov ...
health

6 Awkward Realities That Only People Living With Inflammatory Bowel Disease (IBD) Will Understand

Uncomfortable experiences can be common when you have inflammatory bowel disease (IBD). Find out how people with IBD face ...
USA Herald

Vitamin K Deficiency Bleeding: Why the Newborn Shot Matters and What Parents Should Know

A single injection administered in the first hours of life has become a growing source of uncertainty for some new parents. The newborn vitamin K shot, a preventive dose of a nutrient rather than a ...

Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives

Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in evaluation of strategic initiatives aimed at ...
BIOENGINEER

Ghanaian Pediatric Study Finds Low Coinfection of Malaria and Enteric Pathogens

A cross-sectional investigation at King's Medical Center in Ghana's Kumbungu District identified a 0.4 percent coinfection ...